Monitoring of long-term development and changes in ANS activity by using Training Profile and population standards
Most (certainly we do not know all systems in the world) evaluation approaches using time domains are based solely on comparing an individual's actual results with their previous results. The results say – today it is better than usual, today it is worse than usual. This can also be done using the frequency domain (for mySASY, this is represented by the colour system and the % of compensation level).
However, the interpretation using the available population standard also informs the user about the overall quality of the management and, above all, whether the results are moving in the right direction in the long term = your Training Profile. The examples and their comparison show how positively the adaptation capacity could develop in Athlete 1 (compared to other profiles and development). On the other hand, on the example of Athlete 3, it is possible to demonstrate, in particular, what profile would indicate a minimization of the risk of chronic deterioration, since this athlete can hardly improve his/her adaptation ability (not to be confused with actual performance).
We believe that we have provided you with enough information to decide for yourself how to manage and evaluate your training using HRV. mySASY brings you a unique tool using the spectral analysis (ie frequency domain) to see your training efficiency with maximum accuracy. You get both immediate response and also the long-term perspective, thanks to the Training Profile.
Advanced note: we calculate the time domain parameters and have a clear idea about what kind of information this approach can and can never provide.
*Malik, M., Camm, A. J. Heart rate variability Wiley-Blackwell; 1 edition. Heart rate variability, Standards of measurement, physiological interpretation, and clinical use Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology, European Heart Journal (1996) 17, 354–381.